Baxter International Faces Class Action Over Novum LVP Device Safety Allegations
- Baxter International faces class action lawsuits alleging securities fraud related to its Novum LVP infusion devices' safety and efficacy.
- The company is accused of failing to address known malfunctions of Novum LVP devices, risking patient safety.
- Ongoing litigation could severely impact Baxter's reputation, regulatory standing, and overall business performance if allegations are proven true.
Baxter International Faces Class Action Over Novum LVP Device Allegations
Baxter International Inc. (NYSE: BAX) is currently embroiled in multiple class action lawsuits stemming from allegations of securities fraud related to its Novum LVP infusion devices. The lawsuits, filed by prominent law firms including Rosen Law Firm, Levi & Korsinsky, LLP, and Glancy Prongay & Murray LLP, accuse Baxter of misleading investors regarding the safety and efficacy of the Novum LVP, which reportedly suffers from systemic defects. These defects, such as underinfusion and overinfusion, pose significant risks to patient safety, raising serious concerns about the company's accountability and transparency in its communications with stakeholders.
The allegations detail that Baxter was aware of numerous malfunctions and associated injuries linked to the Novum LVP devices but failed to take appropriate corrective measures or adequately inform the public. This lack of action has led to claims that the company misrepresented the product's safety and sales prospects. The lawsuits, which cover the period from February 23, 2022, to July 30, 2025, invite investors who purchased shares during this timeframe to participate in the legal actions, with a lead plaintiff deadline set for December 15, 2025. Investors are encouraged to seek legal representation as they may be eligible for compensation without incurring any upfront costs.
The implications of these allegations extend beyond financial repercussions for Baxter. The ongoing litigation raises critical questions about the company's commitment to patient safety and ethical business practices. If the accusations are proven true, Baxter could face severe regulatory scrutiny and reputational damage, which may hinder its operational capabilities and investor confidence. Furthermore, the potential withdrawal of existing Novum LVP products from the market could disrupt sales and impact the company’s overall performance, highlighting the importance of transparency and prompt action in addressing safety concerns.
In addition to the ongoing lawsuits, Baxter is urged to reassess its risk management strategies and enhance communication protocols regarding product safety. As the legal proceedings unfold, stakeholders are watching closely to see how Baxter responds to these allegations and whether it takes proactive measures to restore trust with investors and healthcare providers.
Related Cashu News

Merit Medical Systems Launches Employee Stock Ownership Plan to Boost Engagement and Stability
Merit Medical Systems (Ticker: MMSI) recently takes a significant step in enhancing its employee engagement and ownership structure with the launch of a new Employee Stock Ownership Plan (ESOP). The c…

Brookdale Senior Living launches second season of educational podcast "The Grey Take.
Brookdale Senior Living (Ticker: BKD) launches the second season of its popular podcast, "The Grey Take," which serves as a valuable resource for families exploring senior living options. The podcast…

Molina Healthcare Gains Momentum with Increased Risk Adjustment Payments and Positive Revenue Outlook
Molina Healthcare (Ticker: MOH) is making significant strides in its revenue outlook due to recently released risk adjustment figures from the Centers for Medicare & Medicaid Services (CMS). These upd…

Align Technology Faces Antitrust Investigation by European Commission Over Competitive Practices
Align Technology Inc. (Ticker: ALGN) faces a formal antitrust investigation from the European Commission, marking a significant development in the medical devices sector. This inquiry arises from a co…

